Femasys Inc. (FEMY)
| Market Cap | 11.89M -76.2% |
| Revenue (ttm) | 1.97M -4.2% |
| Net Income | -12.14M |
| EPS | -2.62 |
| Shares Out | 8.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,886 |
| Open | 1.460 |
| Previous Close | 1.400 |
| Day's Range | 1.400 - 1.540 |
| 52-Week Range | 1.255 - 20.800 |
| Beta | -2.18 |
| Analysts | Buy |
| Price Target | 16.50 (+1,061.97%) |
| Est. Earnings | Nov 27, 2026 |
About FEMY
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women’s reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It ... [Read more]
Financial Performance
In 2025, Femasys's revenue was $2.29 million, an increase of 40.77% compared to the previous year's $1.63 million. Losses were -$18.63 million, -1.00% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for FEMY stock is "Buy." The 12-month stock price target is $16.5, which is an increase of 1,061.97% from the latest price.
News
Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
$30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financing $30 ...
Femasys Earnings release: Q3 2026
Femasys released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
Femasys Quarterly report: Q3 2026
Femasys has published its Q3 2026 quarterly earnings report on November 13, 2026.
Femasys Slides: Corporate presentation
Femasys has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2026.
Femasys Appoints John Moorhead to Board of Directors
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed t...
Femasys teams with SandsRx Pharmacy to support FemaSeed
Femasys (FEMY) announced an agreement with SandsRx Pharmacy, marking the first in a planned network of specialty pharmacy partnerships supporting the launch of FemaSeed and Femasys’ comprehensive fert...
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients First in a planned network of specialty pharmacy par...
Femasys doubles enrolling sites in FemBloc FINALE Pivotal Trial
Femasys (FEMY) announced that it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States. The coast-to-coast network of academic…
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval -- -- Twelve academic and private cl...
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed t...
Femasys announces Minnesota Women’s Care to implement FemVue
Femasys (FEMY) announced that Minnesota Women’s Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN...
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care
-- Leading multi-site OB/GYN health practice to implement FemVue ® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE...
Femasys partners with CapexMD to expand patient access
Femasys (FEMY) announced a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions. The partnership will support access to FemaS...
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed ...
Femasys registers to sell 28.12M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 28.12M shares of common stock. The company is not selling any…
Femasys Registration statement: Registration filing
Femasys filed a registration statement on September 3, 2026, providing details about a securities offering with the SEC.
Femasys announces fertility partnership with UNC Health
Femasys (FEMY) announced a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue, together with FemaSeed Complete, an in-office intratubal inseminatio...
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEW...
Femasys announces FDA approval of FemBloc modular premarket approval application
Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational non-surgical permanent birth control technology in the ...
Femasys price target lowered to $10 from $30 at Lake Street
Lake Street lowered the firm’s price target on Femasys (FEMY) to $10 from $30 and keeps a Buy rating on the shares. Femasys’ mixed Q2 results are overshadowed by a…
Femasys issued patent for FemBloc blended polymer component
Femasys (FEMY) announced the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the compa...
Femasys price target lowered to $10 from $30 at Maxim
Maxim analyst Jason McCarthy lowered the firm’s price target on Femasys (FEMY) to $10 from $30 and keeps a Buy rating on the shares. The firm cites the company having…
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ...
Femasys Earnings release: Q2 2026
Femasys released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Femasys Quarterly report: Q2 2026
Femasys has published its Q2 2026 quarterly earnings report on August 14, 2026.